EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
Crossref DOI link: https://doi.org/10.1007/s10198-017-0944-0
Published Online: 2017-11-29
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Antoñanzas, F.
Juárez-Castelló, C. A.
Rodríguez-Ibeas, R.
License valid from 2017-11-29